$178M Verdict Against Novartis Stands But Can't Be Tripled

By Dani Kass · September 30, 2022, 9:07 PM EDT

A California federal judge has upheld a jury's $177.8 million infringement verdict against Novartis but overturned the jury's finding that the infringement of a Daiichi Sankyo unit's patents was willful....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

Plexxikon Inc. v. Novartis Pharmaceuticals Corporation

Case Number

Court

California Northern

Nature of Suit

Patent

Date Filed

August 03, 2017

Recent Articles By Dani

July 10, 2024
Drug Pricing, Overreach Dominate IP Disclaimer Feedback
May 28, 2024
Edwards Urges Full Fed. Circ. To Limit FDA Safe Harbor
April 05, 2024
Judge Lourie's Dissent Revives Debate Over FDA Safe Harbor
February 20, 2024
Fed. Circ. Backs Microsoft's PTAB Win Over 3D Patents
February 08, 2024
HHS Won't Invoke IP Rights To Lessen Xtandi Prices
January 30, 2024
CDC Patent Apps Lead Gilead To Victory In HIV Research Feud
January 11, 2024
NJ Judge Not Convinced Epidiolex Seller Lied To USPTO
December 13, 2023
The Biggest Patent Rulings Of 2023
November 17, 2023
FDA's Lack Of Power May Limit FTC's Patent Challenge
November 02, 2023
Nonprofit Calls For CMS-Amgen Price Talks To Reflect Abuse